Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
UNITED KINGDOM RESEARCH AND INNOVATION has 7 pending office actions in Biotechnology & Pharmaceuticals. The profile spans 7 distinct examiners and 5 distinct art units. MOAZZAMI, NAGHMEH NINA is the named busiest examiner, with 1 pending action.
This is a distributed prosecution portfolio rather than a single-channel matter. Counsel should maintain application-specific issue tracking while coordinating terminology and disclosure across the different examiner and art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547085 | FUSION PROTEINS COMPRISING TWO RING DOMAINS | KIEFER, DALTON EDWARD | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | — |
| 18695095 | METHODS OF EDITING NUCLEIC ACID SEQUENCES | WARD, AARON DUREL | — |
| 18690345 | METHODS OF BIOMOLECULE DISPLAY | OLSON, ALEXANDRA NADINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17100889 | CELL PENETRATING MOLECULE | MARTINEZ, TARA L | 75d |
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | — |
| 18690456 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | SWIFT, CANDICE LEE | — |
| 18547085 | FUSION PROTEINS COMPRISING TWO RING DOMAINS | KIEFER, DALTON EDWARD | — |
| 18037063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTESTINAL CANCER | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1684 | 1 |
| 1657 | 1 |
| 1644 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | 1652 | §103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18695095 | METHODS OF EDITING NUCLEIC ACID SEQUENCES | WARD, AARON DUREL | — | §102§103§112Other | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18690345 | METHODS OF BIOMOLECULE DISPLAY | OLSON, ALEXANDRA NADINE | 1684 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690456 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | SWIFT, CANDICE LEE | 1657 | §112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18547085 | FUSION PROTEINS COMPRISING TWO RING DOMAINS | KIEFER, DALTON EDWARD | 1652 | §102§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18037063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTESTINAL CANCER | OUSPENSKI, ILIA I | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 15, 2023 |
| 17100889 | CELL PENETRATING MOLECULE | MARTINEZ, TARA L | 1654 | §112 | Final Rejection | 75d | Pending | Nov 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNITED KINGDOM RESEARCH AND INNOVATION has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Naghmeh Nina Moazzami has the most, with 1 of UNITED KINGDOM RESEARCH AND INNOVATION's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
